WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, Ph.D., Founder, President and CEO, will provide an overview of the Company’s progress and anticipated milestones for 2024.
A live webcast of the presentation and Q&A session will be available under the "Events and Presentations" section of the Investors page on the Company's website at www.kymeratx.com. A replay of the webcast will be archived on Kymera’s website and available for 30-days following the event.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn.
| Investor Contact: Justine Koenigsberg Vice President, Investor Relations This email address is being protected from spambots. You need JavaScript enabled to view it. 857-285-5300 | Media Contact: Todd Cooper Senior Vice President, Corporate Affairs This email address is being protected from spambots. You need JavaScript enabled to view it. 857-285-5300 |
| Last Trade: | US$34.95 |
| Daily Change: | -0.65 -1.83 |
| Daily Volume: | 492,845 |
| Market Cap: | US$2.140B |
May 02, 2024 April 08, 2024 February 22, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
